No. Q5117 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code.

What NDCs are billed under Q5117?

CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 5 NDCs under Q5117, for Kanjinti and Kanjinti (Kit). The table on this page shows each one with its billing units per package.

What is the Medicare payment limit for Q5117?

$63.871 per 10 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.

What is one billing unit of Q5117?

One unit of Q5117 is 10 mg, as stated in the code's descriptor. Units to report = dose given ÷ 10 mg.

Q5117 HCPCS Code: Kanjinti, Kanjinti (Kit)

In short

Q5117 is the HCPCS Level II code for injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg. CMS assigns NDCs for Kanjinti and Kanjinti (Kit) to it. One billing unit is 10 mg. The Medicare Part B payment limit is $63.871 per unit (October 1, 2026 through December 31, 2026).

Code

CMS HCPCS file

HCPCS codeQ5117

Billing unit10 mg

Descriptor: Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
Short descriptor: Inj., kanjinti, 10 mg
Code set: HCPCS Level II, maintained by CMS
Effective: Oct 1, 2019

The billing unit is read from the descriptor. Confirm it against the CMS file before billing.

Medicare Part B payment limit

CMS ASP file

Payment limit per unit$63.871

Per10 mg

Coinsurance20%

Effective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. CMS note: 8% of reference add-on applied. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files

Units and claim line

Units = dose given ÷ 10 mg. For example, 1000 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.

Dose given (mg)

HCPCS units (1 unit = 10 mg)

Modifier

NDC (11-digit)

NDC unit qualifier

NDC quantity

Enter the dose given to build the claim line.

NDCs billed under Q5117

CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 5 NDCs to Q5117 for Kanjinti and Kanjinti (Kit). Billing units per package are CMS’s figures for this code’s unit.

NDCs assigned to Q5117 in the CMS ASP crosswalk
Drug	NDC (11-digit)	Labeler	Package	Billing units per package
Kanjinti	55513-0132-01	Amgen Inc	1	42
Kanjinti	55513-0132-21	Amgen Inc	1	42
Kanjinti	55513-0141-01	Amgen Inc	1	15
Kanjinti	55513-0141-21	Amgen Inc	1	15
Kanjinti (Kit)	55513-0164-01	Amgen Inc	1	42

Q5117: common questions

Is Q5117 a CPT code?: No. Q5117 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
What NDCs are billed under Q5117?: CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 5 NDCs under Q5117, for Kanjinti and Kanjinti (Kit). The table on this page shows each one with its billing units per package.
What is the Medicare payment limit for Q5117?: $63.871 per 10 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
What is one billing unit of Q5117?: One unit of Q5117 is 10 mg, as stated in the code's descriptor. Units to report = dose given ÷ 10 mg. J-code billing units.

Q5117 — Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg